Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

por Abajo, A, Rodriguez, J, Bitarte, N, Zarate, R, Boni, V, Ponz, M, Chopitea, A, Bandres, E, Garcia-Foncillas, J
Publicado 2010

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients

por Abajo, A, Boni, V, Lopez, I, Gonzalez-Huarriz, M, Bitarte, N, Rodriguez, J, Zarate, R, Bandres, E, Garcia-Foncillas, J
Publicado 2012

Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues

por Bandrés, E, Cubedo, E, Agirre, X, Malumbres, R, Zárate, R, Ramirez, N, Abajo, A, Navarro, A, Moreno, I, Monzó, M, García-Foncillas, J
Publicado 2006

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis

por Zarate, R, Rodríguez, J, Bandres, E, Patiño-Garcia, A, Ponz-Sarvise, M, Viudez, A, Ramirez, N, Bitarte, N, Chopitea, A, Gacía-Foncillas, J
Publicado 2010

EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

por Gómez-Benito, M, Conchillo, A, García, M A, Vázquez, I, Maicas, M, Vicente, C, Cristobal, I, Marcotegui, N, García-Ortí, L, Bandrés, E, Calasanz, M J, Alonso, M M, Odero, M D
Publicado 2010